IBA receives down payment from National Cancer Center Korea for a second Proteus System - Seite 2

-ENDS-

About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com

* ProteusPLUS and ProteusONE are the brand name of Proteus235
** Arc Therapy and Flash Therapy are currently under research and development phase and will be available for sale when regulatory clearance is received.

About the National Cancer Center Korea

Korea’s National Cancer Center (NCCK) was established in 2000. It is funded by the Korean Ministry of Health & Welfare and strives to improve national health and welfare by reducing the incidence and mortality of cancer through research, patient care, education and training, and support for national cancer control programs. The National Cancer Center performs 9,022 operations and 8,247 proton therapy treatments per year and publishes about 477 articles annually on cancer in journals indexed in the Science Citation Index.

For further information, please contact:

IBA

Soumya Chandramouli
Chief Financial Officer
[phone]
[e-mail]

Olivier Lechien
Corporate Communication Director
[phone]
[e-mail]

For media and investor enquiries:

Consilium Strategic Communications
Amber Fennell, Angela Gray, Lucy Featherstone, Lizzie Seeley
[phone]
[e-mail]

Attachment

• 20210303-KNCC-ProteusONE-downpayment-EN